Chronic Lymphocytic Leukemia | Specialty

Dr. Byrd on Combination Strategies in CLL

March 5th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the role of combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).

Davids Discusses Frontline CLL Combo of Ibrutinib Plus Chemoimmunotherapy

March 3rd 2018

Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL.

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

March 2nd 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Flinn Highlights Emerging Combinations in CLL

February 26th 2018

Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.

Umbralisib Shows Early Promise in CLL and Lymphoma

February 22nd 2018

The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.

Dr. Barrientos Discusses Combination Strategies in CLL

February 20th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of recent combination trials for patients with chronic lymphocytic leukemia (CLL).

Combinations Continue to Push CLL Field Forward

February 19th 2018

Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.

Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

February 14th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

O'Brien Covers Evolution of Ibrutinib in CLL

February 14th 2018

Susan O’Brien, MD, discusses the impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies in chronic lymphocytic leukemia.

Dr. Tam Discusses the Side Effect Profile of Duvelisib in CLL

February 8th 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the side effect profile of duvelisib in patients with chronic lymphocytic leukemia (CLL).

FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma

February 7th 2018

A new drug application has been submitted to the FDA for duvelisib for a full approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval in relapsed/refractory follicular lymphoma.

Dr. Davids Discusses the Results of Ibrutinib Plus FCR in CLL

February 5th 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses results of a study combining ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in patients with chronic lymphoctic leukemia (CLL).

Dr. Rogers on Benefits of Ibrutinib Combination in CLL

February 1st 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefits of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) and obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).

Dr. Tam Discusses the DUO Trial for CLL

February 1st 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses, the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Dr. Barrientos on the Role of Acalabrutinib in CLL

January 26th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the role of acalabrutinib (Calquence) for patients with chronic lymphocytic leukemia (CLL).

Dr. Davids on Results of Obinutuzumab With Ibrutinib in CLL

January 25th 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia (CLL), discusses the initial results of a phase Ib study of ibrutinib (Imbruvica) in combination with obinutuzumab (Gazyva) in patients with relapsed or refractory CLL.

Dr. Rogers on Determining Patients With High-Risk CLL

January 18th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses how to determine patients with high-risk chronic lymphocytic leukemia (CLL).

Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL

January 12th 2018

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

The Role of Transplant and Future of CLL

January 12th 2018

Other Promising Strategies in CLL

January 12th 2018